Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Considering molecular alterations as pan-cancer tissue-agnostic targets

Nature Cancer volume 4, pages 1622–1626 (2023)Cite this article

Subjects

Owing to high response rates, the Food and Drug Administration has approved both gene- and immune-targeted drugs for tumor-agnostic, genomic biomarker-based indications, for lethal solid and blood cancers. We posit that current data support tissue-agnostic activity as a paradigm, rather than an exception to the rule.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Westin, J. R. & Kurzrock, R. Mol. Cancer Ther. 11, 2549–2555 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hicks, J. K. et al. JCO Precis. Oncol. 5, 884–895 (2021).

    Article  Google Scholar 

  3. Drilon, A. et al. N. Engl. J. Med. 378, 731–739 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kumar, K. R., Chen, W., Koduru, P. R. & Luu, H. S. Am. J. Clin. Pathol. 143, 738–748 (2015).

    Article  CAS  PubMed  Google Scholar 

  5. Lemery, S. et al. Ann. Rev. Cancer Biol. 6, 147–165 (2022).

    Article  Google Scholar 

  6. Subbiah, V. et al. Nat. Med. 28, 1976–1979 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. Clin. Cancer Res. 25, 3753–3758 (2019).

    Article  CAS  PubMed  Google Scholar 

  8. Adashek, J. J., Subbiah, V. & Kurzrock, R. Trends Cancer 7, 15–28 (2021).

    Article  CAS  PubMed  Google Scholar 

  9. Tateo, V. et al. Pharmaceuticals (Basel) 16, 614 (2023).

    Article  CAS  PubMed  Google Scholar 

  10. Verstovsek, S. et al. Blood 140, 3880–3982 (2022).

  11. Adashek, J. J. et al. Mol. Cancer Ther. 21, 871–878 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Corcoran, R. B. et al. J. Clin. Oncol. 33, 4023–4031 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tabernero, J. et al. J. Clin. Oncol. 39, 273–284 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tiacci, E. et al. N. Engl. J. Med. 373, 1733–1747 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pang, Y. et al. JCO Precis. Oncol. 5, 1348–1353 (2021).

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by National Cancer Institute at the National Institutes of Health (NIH) (grant P30 CA023100 (S.K., J.K.S., S.M.L.)). R.K. is funded in part by 5U01CA180888-08 and 5UG1CA233198-05.

Author information

Authors and Affiliations

  1. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, USA

    Jacob J. Adashek

  2. Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA

    Shumei Kato, Jason K. Sicklick & Scott M. Lippman

  3. Department of Surgery, Division of Surgical Oncology, University of California San Diego, UC San Diego Health, San Diego, CA, USA

    Jason K. Sicklick

  4. Department of Pharmacology, University of California San Diego, UC San Diego Health, San Diego, CA, USA

    Jason K. Sicklick

  5. Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA

    Razelle Kurzrock

  6. WIN Consortium, Paris, France

    Razelle Kurzrock

  7. University of Nebraska, Lincoln, NE, USA

    Razelle Kurzrock

Authors
  1. Jacob J. Adashek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shumei Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jason K. Sicklick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott M. Lippman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Razelle Kurzrock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jacob J. Adashek or Razelle Kurzrock.

Ethics declarations

Competing interests

J.J.A. serves on the advisory board of CureMatch Inc and as a consultant for datma. S.K. serves as a consultant for Foundation Medicine. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. J.K.S. receives research funding from Amgen Pharmaceuticals and Foundation Medicine, consultant fees from Deciphera, speaker’s fees from Deciphera, Foundation Medicine, La-Hoffman Roche, Merck, MJH Life Sciences, and QED Therapeutics. SLM is the co-founder of io9 and is on Biological Dynamics, Inc. Scientific Advisory Board. R.K. has received research funding from Biological Dynamics, Boehringer, Caris, Datar Genomics, Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance; as well as consultant and/or speaker fees and/or on the advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Caris, Daiichi Sankyo, Inc., EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics and X-Biotech; has an equity interest in CureMatch Inc., CureMetrix and IDbyDNA; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adashek, J.J., Kato, S., Sicklick, J.K. et al. Considering molecular alterations as pan-cancer tissue-agnostic targets. Nat Cancer 4, 1622–1626 (2023). https://doi.org/10.1038/s43018-023-00676-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00676-y

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer